ReviewEuropean urology2022
Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.
Review in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Diagnostic value of percutaneous sampling in Bosniak III-IV renal cysts: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
- Can risk scoring systems (R.E.N.A.L, PADUA and (MC)2 scoring systems) and related risk factors predict complications of renal ablation? a meta-analysis.Frontiers in oncology · 2026Pooled it
- Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysis.BJU international · 2025Pooled it
- Ultrasound Radiomics for Differential Diagnosis of Renal Masses: A Systematic Review and Meta-Analysis.Technology in cancer research & treatmentPooled it
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- Review
- Differentiating Fat-Poor Angiomyolipoma from Renal Cell Carcinoma Using Contrast-Enhanced CT.Bioengineering (Basel, Switzerland) · 2026Article
- Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours UsingNMR in biomedicine · 2026Article
- Renal oncocytoma remains a diagnostic dilemma: imaging heterogeneity and potential overtreatment in a retrospective cohort.International urology and nephrology · 2026Article
- Artificial Intelligence in the Detection, Characterization, and Management of Renal Masses: A Narrative Review.Cureus · 2026Review
- Application of carbonic anhydrase IX-targeted radiopharmaceuticals in the diagnosis and treatment of clear cell renal cell carcinoma (Review).Oncology letters · 2026Review
- Machine learning pipeline for automated segmentation and classification of complicated cystic renal masses on MRI: comparison with radiologists' assessments.Japanese journal of radiology · 2026Article
- Article
- Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future Directions.Cancers · 2026Review
- Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarisedCommunications medicine · 2026Article
- UBE2S emerges as a key driver in an NK cell-based prognostic model for clear cell renal cell carcinoma.PloS one · 2026Article
- Contrast-enhanced Ultrasound Features of Renal Hemangiomas: A Retrospective Descriptive Study.Current medical imaging · 2026Article
- Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer.Gastro hep advances · 2026Article
- Construction and validation of deep learning-based pathomics signature model for predicting postoperative recurrence of patients with clear cell renal cell carcinoma.American journal of cancer research · 2026Article
- Evaluation of [EJNMMI research · 2025Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
contextThe incidental detection of localized renal masses has been rising steadily, but a significant proportion of these tumors are benign or indolent and, in most cases, do not require treatment. At the present time, a majority of patients with an incidentally detected renal tumor undergo treatment for the presumption of cancer, leading to a significant number of unnecessary surgical interventions that can result in complications including loss of renal function. Thus, there exists a clinical need for improved tools to aid in the pretreatment characterization of renal tumors to inform patient management.
objectiveTo systematically review the evidence on noninvasive, imaging-based tools for solid renal mass characterization. EVIDENCE ACQUISITION: The MEDLINE database was systematically searched for relevant studies on novel imaging techniques and interpretative tools for the characterization of solid renal masses, published in the past 10 yr. EVIDENCE SYNTHESIS: Over the past decade, several novel imaging tools have offered promise for the improved characterization of indeterminate renal masses. Technologies of particular note include multiparametric magnetic resonance imaging of the kidney, molecular imaging with targeted radiopharmaceutical agents, and use of radiomics as well as artificial intelligence to enhance the interpretation of imaging studies. Among these,
conclusionsA number of novel imaging tools stand poised to aid in the noninvasive characterization of indeterminate renal masses. In the future, these tools may aid in patient management by providing a comprehensive virtual biopsy, complete with information on tumor histology, underlying molecular abnormalities, and ultimately disease prognosis. PATIENT SUMMARY: Not all renal tumors require treatment, as a significant proportion are either benign or have limited metastatic potential. Several innovative imaging tools have shown promise for their ability to improve the characterization of renal tumors and provide guidance in terms of patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.